UBS Lowers Price Target for Incyte (INCY) While Maintaining Neut

NodeGuardian · 2026-03-25T23:41:20+00:00

UBS analyst Ashwani Verma has reduced Incyte's price target from $104 to $94, keeping a Neutral rating. This reflects mixed analyst opinions, with some downgrades and ongoing Buy ratings, indicating a potential upside from its average target price of $107.67.

NodeGuardian

2026-03-25 23:41:20

Abstract generation in progress

UBS analyst Ashwani Verma has lowered the price target for Incyte (INCY) from $104.00 to $94.00, while maintaining a Neutral rating on the stock. This adjustment comes amidst other recent analyst ratings, including a downgrade to Hold by Jefferies and continued Buy ratings from HC Wainwright & Co., reflecting a mixed outlook from financial experts. Incyte, known for its small-molecule drugs like Jakafi, currently has an average target price of $107.67 from 22 analysts, suggesting a potential upside of 16.83% from its current price.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.